NEW PATENT GRANT UNDERPINS GROWTH OPPORTUNITIES FOR COMPUMEDICS’ DWL

• New product development based on patent for system of detecting and treating blood vessel stenosis or occlusions
• Wider ultrasound and stroke treatment markets to be accessed – US$1.9 billion
  Traumatic Brain Injury (TBI) costs estimated at US$76.5 billion
• Clear focus on commercialising patent portfolio and shareholder realisation

Compumedics Limited (ASX: CMP) (“Compumedics” and “Company”) is pleased to announce that the Company’s Germany-based, brain blood-flow Doppler-sonography division, Compumedics Germany GmbH(“DWL”), has been awarded a new European patent for a new approach to ultrasound diagnosis and treatment of stroke.

DWL intends to develop an automatic system for detecting and treating blood vessel stenosis or occlusion for the prevention and treatment of stroke as well as a monitor system for TBI.

In commenting on the European patent, Mr Christoph Witte, Managing Director of DWL, said:

“We are pleased to reveal, following many years of research, our new granted patent’s important role in management of two primary growth areas associated with stroke and traumatic brain injury.

“In particular we have combined the latest principles and technology behind automated tracking and treatment management of vascular dysfunction associated with traumatic brain injury (TBI) along with similar potential functionality during stroke management.

“This system will simplify the current, largely manual, process for assessing blood flow through the brain, expanding significantly the potential application of the automatic device into new and existing markets.”

In commenting on Compumedics’ research and development, Dr David Burton, Chairman and CEO of the Compumedics Group, said:

“This patent is an important achievement for DWL and its parent company Compumedics, as it underpins DWL’s superior reputation in the areas of research and development.”

“We are encouraged that our technology has already been deployed and is the subject of a number of reports relating to the deployment, within the US Department of Health, where there is a growing need to remotely and automatically diagnose TBI.”

The patent covers a servo-controllable transducer, which allows automatic signal detection in the brain supplying arteries as well as the discovery of narrowing (stenosis or occlusion) in the arterial system. Blood vessel stenosis or occlusions are characteristic of 80% of strokes.

About Compumedics Limited

Compumedics Limited (ASX: CMP) is a medical device company involved in the development, manufacture and commercialisation of diagnostics technology for the sleep, brain and ultrasonic blood-flow monitoring applications. The Company owns US based Neuroscan and Germany based DWL Elektronishe GmbH. In conjunction with these two subsidiaries, Compumedics has a broad international reach, including Americas; Australia and Asia Pacific; and Europe and the Middle East.

Executive Chairman, Dr David Burton, founded Compumedics in 1987. In the same year the Company successfully designed and installed the first Australian, fully computerised Sleep Clinic at Epworth Hospital in Melbourne. Following this early success, Compumedics focused on the development of products that sold into the growing international sleep clinic and home monitoring markets. Compumedics listed on the Australian Securities Exchange in 2000. Over the years, Compumedics has received numerous awards and accolades including Australia’s exporter of the year and has been recognised as a Top 100 Innovatorby the both German and Australian Governments.